Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	35.26	12.47	25.29	30.61	31.83
Short-Term Investments	67.96	121.14	207.64	171.12	259.41
Cash & Short-Term Investments	103.21	133.61	232.94	201.73	291.23
Cash Growth	-22.75%	-42.64%	15.47%	-30.73%	33.40%
Other Current Assets	2.48	2.28	2.65	2.65	3.88
Total Current Assets	105.69	135.9	235.59	204.38	295.12
Net Property, Plant & Equipment	32.28	35.47	37.74	6.7	5.64
Other Long-Term Assets	3.35	4.15	4.34	9.42	4.35
Total Assets	141.32	175.52	277.67	220.5	305.1
Accounts Payable	3.98	7.73	4.58	6.78	7.84
Accrued Expenses	12.53	15.21	15.77	13.09	9.62
Current Portion of Leases	2.74	2.7	1.48	1.83	1.74
Unearned Revenue	33.73	-	-	-	-
Total Current Liabilities	52.99	25.64	21.83	21.7	19.2
Long-Term Leases	15.05	15.33	18.75	-	-
Other Long-Term Liabilities	4.64	3.09	-	3.36	-
Total Long-Term Liabilities	19.68	18.42	18.75	3.36	-
Total Liabilities	72.68	44.06	40.58	25.06	19.2
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	751.68	714.98	693.25	531.68	505.72
Accumulated Other Comprehensive Income	0.01	0.04	0.22	-1.69	-0.71
Retained Earnings	-683.06	-583.56	-456.39	-334.56	-219.12
Shareholders' Equity	68.64	131.46	237.09	195.44	285.9
Total Liabilities & Equity	141.32	175.52	277.67	220.5	305.1
Total Debt	17.79	18.03	20.23	1.83	1.74
Net Cash (Debt)	85.43	115.59	212.71	199.9	289.49
Net Cash Growth	-26.10%	-45.66%	6.41%	-30.95%	32.61%
Net Cash Per Share	1.11	1.52	3.52	4.22	6.29
Book Value	68.64	131.46	237.09	195.44	285.9
Book Value Per Share	0.89	1.73	3.93	4.13	6.21
Tangible Book Value	68.64	131.46	237.09	195.44	285.9
Tangible Book Value Per Share	0.89	1.73	3.93	4.13	6.21

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q